SARS-CoV-2

[Nature Methods] Scientists overview the current effort to apply both human pluripotent stem cell-derived organoids and adult organoids to study SARS-CoV-2 tropism, host response and immune cell-mediated host damage, and perform drug discovery and vaccine development.

[Journal of Controlled Release] Researchers developed a formulation for pulmonary administration of siRNA to suppress SARS-CoV-2 replication in lung epithelial cells.

[Nature Nanotechnology] The authors share lessons learned over a decade of nanomedicine research and discuss the current knowledge about several factors that individually or collectively contribute to infusion reactions to nanomedicines.

[Science Translational Medicine] Given our emerging appreciation for the importance of additional antibody functions beyond neutralization, we profiled the post-boost binding and functional capacity of humoral immune responses induced by the BNT162b2 and mRNA-1273 vaccines in a cohort of hospital staff.

[Lancet Infectious Diseases] Using national COVID-19 notification, hospitalization, and vaccination datasets from Brazil, researchers did a test-negative, case-control study to assess the effectiveness of four vaccines for individuals with laboratory-confirmed previous SARS-CoV-2 infection.

[Nature Reviews Neurology] The authors discuss what is known about the effects of various immunotherapies on immunological responses to vaccines and what these effects mean for the safe and effective use of vaccines in patients with a neuroimmunological disease.